Ultimovacs Publishes Phase II FOCUS Trial Results on medRxiv

**Ultimovacs Publishes Phase II FOCUS Trial Results on UV1 Cancer Vaccine**

Oslo, October 25, 2024: Ultimovacs ASA, a clinical-stage biotechnology enterprise specializing in cancer immunotherapeutic vaccines, has released the findings from its Phase II FOCUS trial (NCT05075122) on the preprint platform medRxiv. The study evaluated the efficacy of combining UV1 with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC). Despite demonstrating a positive safety profile, the trial did not achieve its primary and secondary endpoints related to progression-free survival (PFS) and overall survival (OS).

The FOCUS trial, formally known as the First-line metastatic Or recurrent HNSCC/Checkpoint inhibitor UV1 Study, is a randomized, open-label Phase II clinical trial driven by investigators. The principal aim was to ascertain the clinical benefits of adding UV1 to the standard pembrolizumab regimen. The study was designed for patients who receive pembrolizumab as either a first-line treatment for metastatic HNSCC or as a second-line therapy for recurrent PD-L1 positive HNSCC. The trial is under the leadership of Professor Mascha Binder from the Medical Faculty, University of Halle-Wittenberg, Germany.

Since the first patient enrollment in August 2021, the FOCUS trial has been conducted across ten sites in Germany. A total of 75 patients were randomized in a 2:1 ratio, with 50 patients receiving the combination of UV1 and pembrolizumab, while the remaining 25 patients were treated with pembrolizumab alone. The primary endpoint was the PFS rate six months post the initial administration of the study drug. Secondary endpoints included overall survival, objective response rate (ORR), duration of response (DOR), and safety, all monitored over a minimum follow-up period of 12 months.

The topline data indicated that the addition of UV1 to pembrolizumab did not result in improved clinical outcomes in terms of PFS or OS, leading to the conclusion that the trial did not meet its key objectives. However, UV1 continued to exhibit a favorable safety profile, consistent with previous studies, and showed good tolerability, similar to the control arm.

UV1 is a universal cancer vaccine intended to elicit a targeted T cell response against telomerase. The vaccine comprises synthetic long peptides mirroring a sequence within the reverse transcriptase subunit of telomerase (hTERT), which activates CD4+ T cells. These T cells are crucial for driving a potent anti-tumor immune response. Upon intradermal administration, the vaccine peptides are presented by antigen-presenting cells (APCs) in the skin to naïve T cells in the lymph nodes. The activated T cells then circulate to identify and attack cells presenting the specific antigens.

UV1's peptide composition includes various epitopes that do not require Human Leukocyte Antigen (HLA) pre-screening, allowing for broader patient applicability. The vaccine is delivered via eight intradermal injections over three months, alongside the immune-modulator GM-CSF.

Ultimovacs ASA is dedicated to advancing novel cancer immunotherapies. Their primary product, UV1, is an off-the-shelf cancer vaccine designed to enhance the effectiveness of current immunotherapies, targeting telomerase, a common antigen found in most cancers. Their extensive clinical development program includes multiple Phase II trials across different cancer types such as melanoma, mesothelioma, head and neck cancer, ovarian cancer, and non-small cell lung cancer, involving over 640 patients globally.

In addition, Ultimovacs is exploring a novel conjugation technology aimed at expanding their vaccine pipeline. This technology is versatile, potentially applicable to a range of therapeutic modalities including innovative drug conjugates with favorable pharmacological characteristics, and is being developed to support future growth in various disease areas.

Ultimovacs is publicly listed on the Euronext Oslo Stock Exchange under the ticker OSE:ULTI.